You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Psoriatic arthritis
FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016300
Aug 2016502
Sep 2016002
Oct 20161601
Nov 20161401
Dec 20162701
Jan 20171100
Feb 20171500
Mar 20171801
Apr 20171201
May 20171003
Jun 20171100
Jul 20171400
Aug 20173001
Sep 20171800
Oct 20171602
Nov 20173004
Dec 2017800
Jan 20183002
Feb 20182802
Mar 20182801
Apr 20185004
May 20181200
Jun 20182002
Jul 20181400
Aug 20181200
Sep 20181601
Oct 20182402
Nov 20181605
Dec 2018600
Jan 2019801
Feb 2019401
Mar 20191000
Apr 2019400
May 20192200
Jun 2019602
Jul 20193001
Aug 2019400
Sep 2019800
Oct 20192001
Nov 2019200
Dec 20191800
Jan 2020200
Feb 2020001
Apr 2020400
Jun 2020400
Jul 2020600
Sep 20201600
Oct 2020200
Nov 2020700
Dec 2020200
Jan 2021400
Feb 2021200
Mar 2021201
May 2021001
Oct 20211200
Nov 20212900
Dec 20211200
Jan 2022200
Feb 2022800
Mar 2022200
May 20221200
Jun 2022600
Jul 2022400
Aug 20221000
Sep 20221400
Oct 20221400
Nov 2022600
Dec 20221400
Jan 2023200
Feb 2023600
Mar 2023400
May 2023400
Jun 2023200
Jul 2023400
Sep 20231800
Oct 2023200
Nov 2023800
Dec 20231200
Jan 2024200
Feb 2024400
Mar 2024200
Total916047